Is this you?
Request access for Lucas Research with your @lucasresearch.org work email. Intera will contact you to verify and set up your account — nothing auto-publishes.
Lucas Research
Unclaimed profileSite Network · Morehead City, NC · ~5 sites
Intera lens
ICP 6Lift (cardio sample) 0.71Recruit soph 0.29
Quality Scorecard (1–100)
Overall84Recruit73Ops86Sponsor93Ther86
Performance (observed)
Historical trials
600
Completed
280
Terminated/Withdrawn
70
Completion rate
80%
Active now
246
Phase 2
146
Phase 3
403
Realized enrollment
848,966
First study year
1999
Years active
27
Match confidence
low
Enrollment velocity (inf)
31,443
Therapeutic
Areas
Diabetes, NASH, Obesity, GI, Endocrinology, Neurology
Specialties
Endocrinology, Phase 1, Neurology (diabetes, obesity, metabolic)
Breadth (conditions)
487
States
NC
Recruitment (web observed)
Recruitment pages
Yes
Advertises recruitment
Yes
SEO
Patient-focused recruitment
Capability notes
#1 recruiting site in 28+ studies globally; strong enrollment track record in metabolic/endocrine indications
Relationships
Sponsors
Hoffmann-La Roche; Eli Lilly and Company; Pfizer; Janssen Research & Development, LLC; Merck Sharp & Dohme LLC; Sanofi
CROs
ICON Clinical Research; IQVIA Pty Ltd; PPD Development, LP; PSI CRO; Parexel; Syneos Health
Owner / parent
Acquired by Centricity Research (2023)
Acquisitions
ACQUIRED by Centricity Research (Dec 2023)
Expansion
5 sites in North Carolina
Capacity & people
Investigators
—
Coordinators
—
CEO
Seth Medlin
VP Clinical Ops
Unknown
VP Site Ops
Unknown
VP Recruitment
Unknown
Emails
252-222-5700 (phone)
Tech & DCT
Builds tech
Unknown
Recruiting visible
Y
Notes
Founded 2004 by Dr. K. Jean Lucas & Seth Medlin. 5 sites in NC (Morehead City HQ, Phase 1, Neurology, New Bern, Hickory endocrinology). 50+ person team. Top-tier enrolling site in diabetes, NASH, obesity, GI studies. Recent acquisition by Centricity Research adds scale. Good Intera fit: strong enrollment capability, focused therapeutic areas, recruitment track record. [Validated: 9 active recruiting cardiometabolic trials on ClinicalTrials.gov.]
Recommendation features (sample indication)
Ind fit 1.00Liftability 0.71Overall84
FUTURE MOAT: absolute enrollment rates, funnel CPR, measured SSU, screen-fail reasons.